Publikationen von M. Zweckstetter

Zeitschriftenartikel (242)

Zeitschriftenartikel
Kohfeldt, E.; Göhring, W.; Mayer, U.; Zweckstetter, M.; Holak, T. A.; Chu, M. L.; Timp, R.: Conversion of the Kunitz-type module of collagen VI into a highly active trypsin inhibitor by site-directed mutagenesis. FEBS Journal 238 (2), S. 333 - 340 (1996)
Zeitschriftenartikel
Zweckstetter, M.; Czisch, M.; Mayer, U.; Chu, M. L.; Zinth, W.; Timpl, R.; Holak, T. A.: Structure and multiple conformations of the Kunitz-type domain from human type VI collagen alpha3(VI) chain in solution. Structure 4 (2), S. 195 - 209 (1996)

Konferenzbeitrag (7)

Konferenzbeitrag
Oroz, J.; Chang, B. J.; Wysoczanski, P.; Lee, C. T.; Perez-Lara, A.; Chakraborty, P.; Hofele, R. V.; Baker, J. D.; Blair, L. J.; Biernat, J. et al.; Urlaub, H.; Mandelkow, E.; Dickey, C. A.; Zweckstetter, M.: Structure and pro-toxic mechanism of the human Hsp90/PPIase/Tau complex. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, 04. Mai 2019 - 10. Mai 2019. Neurology 92 (Suppl), P1.1-006, (2019)
Konferenzbeitrag
Robustelli, P.; Piana-Agostinetti, S.; Ibanez de Opakua, A.; Giordanetto, F.; Campbell-Bezat, C. K.; Becker, S.; Pan, A. C.; Zweckstetter, M.; Shaw, D. E.: Improved physical models enable the investigation of molecular recognition in intrinsically disordered proteins at atomistic rsolution. 63rd Annual Meeting of the Biophysical-Society, Baltimore, MD, 02. März 2019 - 06. März 2019. Biophysical Journal 116 (Suppl_1), S. 303A - 303A (2019)
Konferenzbeitrag
Rauscher, S.; Gapsys, V.; Zhou, M.; Van, Q.; Gajda, M. J.; Zweckstetter, M.; Enderlein, J.; de Groot, B. L.; Grubmüller, H.: Structural ensembles of intrinsically disordered proteins depend strongly on force field: A comparison to experiment. 60th Annual Meeting of the Biophysical-Society, Los Angeles, CA, 27. Februar 2016 - 02. März 2016. Biophysical Journal 110 (Suppl 1), 3 Aufl., S. 358A - 358A (2016)
Konferenzbeitrag
Zweckstetter, M.: Intrinsically disordered proteins in neurodegeneration. 60th Annual Meeting of the Biophysical-Society, Los Angeles, CA, 27. Februar 2016 - 02. März 2016. Biophysical Journal 110 (Suppl 1), 3 Aufl., S. 2a - 2a (2016)
Konferenzbeitrag
Levin, J.; Wagner, J.; Ryazanov, S.; Leonov, A.; Shi, S.; Schmidt, F.; Prix, C.; Bertsch, U.; Mitteregger-Kretzschmar, G.; Geissen, M. et al.; Hischberger, T.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Baehr, M.; Weishaupt, J.; Uhr, M.; Urlaub, H.; Teichmann, U.; Boetzel, K.; Groschup, M.; Kretzschmar, H. A.; Griesinger, C.; Giese, A.: Causal therapy of Parkinson's disease with anle138b, a novel protein aggregation inhibitor. 15th International Congress of Parkinsons Disease and Movement Disorders, Toronto, CANADA, 2011. Movement Disorders 26 (Supplement 2), S. S21 - S21 (2011)
Konferenzbeitrag
Montaville, P.; Kim, H. Y.; Vijayan, V.; Becker, S.; Zweckstetter, M.: H-1, N-15, and C-13 resonance assignment of the C2A domain of rabphilin3A. Journal of Biomolecular NMR 36 (Suppl. 1), S. 20 - 20 (2006)
Konferenzbeitrag
Bertoncini, C. W.; Cherny, D. I.; Fernandez, C. O.; Garfinkel, E.; Griesinger, C.; Hoyer, W.; Jares-Erijman, E. A.; Jovin, T. M.; Marsh, D.; Rasia, R. M. et al.; Roberti, M. J.; Subramaniam, V.; Zweckstetter, M.: 3D structure, ligand binding, autoinhibition, aggregation, and cellular distribution of wild-type, mutant, and labeled alpha-synuclein. Biophysical Journal 88 (1), S. 396A - 396A (2005)

Meeting Abstract (1)

Meeting Abstract
Villinger, S.; Briones, R.; Giller, K.; Zachariae, U.; Lange, A.; de Groot, B. L.; Griesinger, C.; Becker, S.; Zweckstetter, M.: Functional dynamics in the voltage-dependent anion channel. In FEBS Journal, 279 (Suppl. 1), P20-86, S. 433 - 433. 22nd IUBMB Congress/37th FEBS Congress, Seville/Spain, 04. September 2012 - 09. September 2012. (2012)

Patent (1)

Patent
Zweckstetter, M.; Karpinar, P.; Griesinger, C.: Mutant alpha-synuclein with increased toxicity. WO/2010/015714 (2010)
Zur Redakteursansicht